1-(4-fluorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole | 1373918-57-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-fluorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
• 英文别名: 1-(4-fluorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole
• CAS: 1373918-57-0
• 化学式: C₁₅H₁₈BFN₂O₂
• 分子量: 288.13
• InChiKey: RZFHDSVXXCMHAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.31
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  36.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-fluorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium hydride 、 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 17.17h， 生成 3-(benzyloxy)-5-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)-4-methylpicolinonitrile
  参考文献：
  名称：

  [EN] PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
  [FR] COMPOSÉS INHIBITEURS DE PHD, COMPOSITIONS ET PROCÉDÉS D'UTILISATION

  摘要：

  本发明部分提供了PHD的新型小分子抑制剂，其结构符合公式（I），以及其子公式：或其药用可接受的盐。本文提供的化合物可用于治疗包括心脏（如缺血性心脏病、充血性心力衰竭和心瓣膜疾病）、肺（如肺部炎症、肺炎、急性肺损伤、肺动脉高压、肺纤维化和慢性阻塞性肺病）、呼吸系统（如呼吸道感染、急性呼吸窘迫综合征）、肝（如急性肝功能衰竭和肝纤维化和肝硬化）和肾（如急性肾损伤和慢性肾病）疾病、炎症性肠病（IBD）、缺血再灌注损伤（如中风）和早产儿视网膜病变（ROP）等疾病的治疗。

  公开号：

  WO2022036188A1
• 作为产物：
  描述：

  1-(4-fluorophenyl)-1H-pyrazole 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 溴 、 potassium acetate 、 溶剂黄146 作用下， 以 1,4-二氧六环 为溶剂， 生成 1-(4-fluorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
  参考文献：
  名称：

  Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues

  摘要：

  The structural diversity and SAR in a series of imidazopyridazine inhibitors of Plasmodium falciparum calcium dependent protein kinase 1 (PfCDPK1) has been explored and extended. The opportunity to further improve key ADME parameters by means of lowering log D was identified, and this was achieved by replacement of a six-membered (hetero)aromatic linker with a pyrazole. A short SAR study has delivered key examples with useful in vitro activity and ADME profiles, good selectivity against a human kinase panel and improved levels of lipophilic ligand efficiency. These new analogues thus provide a credible additional route to further development of the series. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.010

文献信息

• [EN] NURR1 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR NURR1
  申请人：UNIV CALIFORNIA

  公开号：WO2020172324A8

  公开（公告）日：2021-08-26
• [EN] PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE<br/>[FR] COMPOSÉS INHIBITEURS DE PHD, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：AKEBIA THERAPEUTICS INC

  公开号：WO2022036188A1

  公开（公告）日：2022-02-17

  The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g., respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), and retinopathy of prematurity (ROP).

  本发明部分提供了PHD的新型小分子抑制剂，其结构符合公式（I），以及其子公式：或其药用可接受的盐。本文提供的化合物可用于治疗包括心脏（如缺血性心脏病、充血性心力衰竭和心瓣膜疾病）、肺（如肺部炎症、肺炎、急性肺损伤、肺动脉高压、肺纤维化和慢性阻塞性肺病）、呼吸系统（如呼吸道感染、急性呼吸窘迫综合征）、肝（如急性肝功能衰竭和肝纤维化和肝硬化）和肾（如急性肾损伤和慢性肾病）疾病、炎症性肠病（IBD）、缺血再灌注损伤（如中风）和早产儿视网膜病变（ROP）等疾病的治疗。
• Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues
  作者：Jonathan M. Large、Simon A. Osborne、Ela Smiljanic-Hurley、Keith H. Ansell、Hayley M. Jones、Debra L. Taylor、Barbara Clough、Judith L. Green、Anthony A. Holder

  DOI：10.1016/j.bmcl.2013.08.010

  日期：2013.11

  The structural diversity and SAR in a series of imidazopyridazine inhibitors of Plasmodium falciparum calcium dependent protein kinase 1 (PfCDPK1) has been explored and extended. The opportunity to further improve key ADME parameters by means of lowering log D was identified, and this was achieved by replacement of a six-membered (hetero)aromatic linker with a pyrazole. A short SAR study has delivered key examples with useful in vitro activity and ADME profiles, good selectivity against a human kinase panel and improved levels of lipophilic ligand efficiency. These new analogues thus provide a credible additional route to further development of the series. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.